{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:09:25Z","timestamp":1795039765017,"version":"4.10.2"},"reference-count":75,"publisher":"Informa UK Limited","issue":"2","license":[{"start":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T00:00:00Z","timestamp":1731196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"National Institute for Healthcare Research","award":["CL-2022-07-001"],"award-info":[{"award-number":["CL-2022-07-001"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1080\/17425255.2024.2427310","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T10:33:31Z","timestamp":1730975611000},"page":"115-123","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":33,"title":["Cefepime\/Enmetazobactam: a microbiological, pharmacokinetic, pharmacodynamic, and clinical evaluation"],"prefix":"10.1080","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5400-3413","authenticated-orcid":false,"given":"Christopher A","family":"Darlow","sequence":"first","affiliation":[{"name":"University of Liverpool","place":["Liverpool, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6187-878X","authenticated-orcid":false,"given":"William","family":"Hope","sequence":"additional","affiliation":[{"name":"University of Liverpool","place":["Liverpool, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3793-1469","authenticated-orcid":false,"given":"Vineet","family":"Dubey","sequence":"additional","affiliation":[{"name":"University of Liverpool","place":["Liverpool, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,11,10]]},"reference":[{"key":"e_1_3_4_3_1","unstructured":"World Health Organization. Global antimicrobial resistance and use surveillance system (\u200eGLASS)\u200e report: 2022. 2022. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240062702"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki130"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00036-08"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-1400-1_12"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix893"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12040761"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2018.1447381"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-021-00465-z"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.6.6.805"},{"issue":"3","key":"e_1_3_4_12_1","first-page":"369","article-title":"Cefepime: the next generation?","volume":"17","author":"Sanders CC","year":"1993","unstructured":"Sanders CC. Cefepime: the next generation? Clin Infect Dis. 1993;17(3):369\u2013379.","journal-title":"Clin Infect Dis"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.39.1092"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.41.86"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.1.269-275.2004"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-011-1183-4"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.6.2206-2212.2001"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2005.01.005"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00105-19"},{"key":"e_1_3_4_20_1","unstructured":"Orchid Chemicals & Pharm Ltd. Patent for 2-substituted methyl penam derivatives [internet]. Report No.: US7687488B2. 2010. Available from: https:\/\/worldwide.espacenet.com\/patent\/search\/family\/038949982\/publication\/US7687488B2?q=pn%3DUS7687488"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.11.2312"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01793-21"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens4030620"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2022.2021876"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01676-21"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00339-23"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00514-19"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2021.08.012"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105925"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106377"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2021.02.031"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-011-1333-8"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.0c00682"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00607-19"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00926-21"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106738"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.11.1831"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/32.suppl_B.63"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005453"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107150"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2006.06.014"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03530.x"},{"key":"e_1_3_4_43_1","unstructured":"Allecra Therapeutics. Exblifep - summary of product characteristics Available from: http:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/exblifep"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.3.552"},{"issue":"1","key":"e_1_3_4_45_1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0090-9556(25)07107-7","article-title":"Disposition of the cephalosporin cefepime in normal and renally impaired subjects","volume":"19","author":"Barbhaiya RH","year":"1991","unstructured":"Barbhaiya RH, Knupp CA, Forgue ST, et al. Disposition of the cephalosporin cefepime in normal and renally impaired subjects. Drug Metab Dispos. 1991;19(1):68\u201373.","journal-title":"Drug Metab Dispos"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/22.6.911"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.27.2.207"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.1.55"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00033-15"},{"key":"e_1_3_4_50_1","unstructured":"Renascience Pharma Ltd. Renapime 2g powder for solution for injection\/infusion - summary of product characteristics [Internet]. 2018. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/9672\/smpc#gref"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01468-20"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.23.3.310.32108"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/24.1.23"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00078-20"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00180-20"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41429-022-00592-w"},{"key":"e_1_3_4_57_1","unstructured":"Allecra. A phase 1 open-label single-dose study to assess the Mass balance pharmacokinetics and metabolism of intravenously administered 14C-AAI101 in healthy male subjects. Report No.: nCT03775668. clinicaltrials.gov; 2019 [cited 2024]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03775668"},{"key":"e_1_3_4_58_1","unstructured":"Allecra. Phase 1 open-label parallel group single-dose study to evaluate the pharmacokinetics safety and tolerability of AAI101 with cefepime in subjects with varying degrees of renal function. Report No.: nCT03680352. clinicaltrials.gov; 2022 [cited 2024]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03680352"},{"key":"e_1_3_4_59_1","unstructured":"Allecra. Randomized double-blind multi-center study of Cefepime\/AAI101 in hospitalized adults with complicated urinary tract infections including acute pyelonephritis. Report No.: nCT03680612. clinicaltrials.gov; 2018 [cited 2024]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03680612"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.17034"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.6.954"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/28.4.569"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-017-1856-1"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks012"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(03)00188-6"},{"key":"e_1_3_4_66_1","unstructured":"UK Tetralogy Information Service. Use of cephalosporins in pregnancy. Report No.: v4. 2022. Available from: https:\/\/uktis.org\/monographs\/use-of-cephalosporins-in-pregnancy\/"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac271"},{"key":"e_1_3_4_68_1","unstructured":"Food and Drug Administration. Drug approval package: EXBLIFEP [Internet]. Report No.: 216165. 2024. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/216165Orig1s000TOC.cfm"},{"key":"e_1_3_4_69_1","unstructured":"European Medicines Agency. Exblifep: EPAR - Medicine overview. Report No.: eMA\/52694\/2024. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/exblifep"},{"key":"e_1_3_4_70_1","unstructured":"Combined antibiotic approved to treat adult patients with severe infections of the urinary tract and hospital-acquired pneumonia. MHRA; [cited 2024 Apr 10]. Available from: https:\/\/www.gov.uk\/government\/news\/combined-antibiotic-approved-to-treat-adult-patients-with-severe-infections-of-the-urinary-tract-and-hospital-acquired-pneumonia"},{"key":"e_1_3_4_71_1","unstructured":"European Medicines Agency. Exblifep: EPAR - Public assessment report - EMA\/63929\/2024 [Internet]. 2024. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/exblifep#assessment-history"},{"key":"e_1_3_4_72_1","unstructured":"Allecra. Single group phase 2 study to investigate pharmacokinetics safety and tolerability of cefepime-enmetazobactam administered by IV over 2\u00a0hr in male or female participants from birth to less than 18 years of age hospitalised with cUTI. Report No.: nCT05826990. clinicaltrials.gov; 2024 [cited 2024]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05826990"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab468"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9020061"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11040493"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1665022"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a027029"}],"container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2024.2427310","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T23:00:45Z","timestamp":1738364445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425255.2024.2427310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,10]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1080\/17425255.2024.2427310"],"URL":"https:\/\/doi.org\/10.1080\/17425255.2024.2427310","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"value":"1742-5255","type":"print"},{"value":"1744-7607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-07-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}